Search Results for "Adaptimmune Human Trials Results 2011"
Original Source: Adaptimmune announces Opening of Phase I/II Clinical Trial for Metastatic Melanoma at Washington University, St. Louis
(Oxford, UK) 13 June, 2011. Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri. Adaptimmune is focused on the use of T-cell therapy to treat cancer, with the body’s own machinery - the T lymphocyte-- a cell that is being used to target and destroy cancerous cells. This trial is designed to investigate the safety, bioactivity and anti-tumor effect of patients’ own T cells th...
Matching Channels
Matching News
Immunocore & Adaptimmune: Battling Cancer
James Noble, CEO of both Immunocore and Adaptimmune joined Fintan Walton at BioTrinity to talk through the separate business models the two companies have despite having been founded with the same pla...
NeoStem’s (NYSE MKT: NBS) New contract for PCT
PCT enters Into a Cell Therapy Manufacturing Services Agreement with Adaptimmune NBS’ Progenitor Cell Therapy (PCT) to provide Cell Product Development and Manufacturing for Adaptimmune...
16 November, 2012: Oxford, UK and Philadelphia, USA - Adaptimmune announces the publication of dual abstracts in today's issue of the Journal Blood, which report preliminary results from ...
16 January 2013: Allendale, USA, & Oxford, UK, – NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy LLC, together with Adaptimmune Limited and Adaptimmune LLC ...
10 December 2012: Atlanta, USA and Oxford, UK - Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients' own T cells that have been ...
Abstracts Published in Today’s Issue of the Journal Blood (Oxford, UK and Philadelphia, PA) 16 November, 2012. Adaptimmune announces the publication of dual abstracts in today’s issue of...
Study reports encouraging response rates, and data support safety and preliminary proof of mechanism (Atlanta, GA and Oxford, UK) 10 December, 2012. Adaptimmune today announces the release of prelimi...
(Oxford, UK and Philadelphia, PA) 7 March 2011. Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Sc...
Matching PubMed Articles
Landscape and evolution of therapeutic research for breast cancer patients.
Breast cancer survival rates have improved, new disease classifications have been adopted, and increased awareness about symptom management has arisen. Nevertheless, it is unknown to what extent these...
Progress and prospects: hurdles to cardiovascular gene therapy clinical trials.
Several gene therapy approaches have been designed for the treatment of cardiovascular diseases. A positive finding is that the safety of cardiovascular gene therapy has been excellent even in long-te...
Converting human skin cells to neurons: a new tool to study and treat brain disorders?
Recent publications in Cell Stem Cell (Son et al., 2011; Ambasudhan et al., 2011), PNAS (Pfisterer et al., 2011), and Nature (Caiazzo et al., 2011; Pang et al., 2011; Yoo et al., 2011) report th...
The authors performed a systematic review and meta-analysis to evaluate whether there is a beneficial clinical effect of total disk replacement compared with anterior cervical diskectomy and fusion fo...
This article provides information and commentaries on trials, which were presented during the Hotline Sessions at the 77th annual spring meeting of the German Society of Cardiology in Mannheim, German...
